BOSTON, MA, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- ValueSetters, Inc. (OTC:VSTR) announced today the successful completion of a private capital raise for Phoenix PharmaLabs, one of the company’s digital marketing clients.  ValueSetters assisted with the Reg CF portion of the raise, which was oversubscribed on the Netcapital platform.

“The ValueSetters team was proud and honored to work with Phoenix PharmaLabs, a company that is working to address the opioid crisis with their non-addictive pain killer,” said Cecilia Lenk, CEO of ValueSetters. “Phoenix PharmaLabs has a powerful mission.  More than 2 million Americans are seriously addicted to opioids, and the funds that were raised in their offering will be used to help address this national crisis.”

“ValueSetters played a critical role in the success of our offering,” said Bill Crossman, President & CEO of Phoenix PharmaLabs.  “Their unique expertise in the digital marketing of private capital raises drove significant investment dollars. They really rose to the challenge, and we were pleased with their collaborative approach.”

Jackson Stone, Head of Business Development at Netcapital, added, “We referred Phoenix PharmaLabs to ValueSetters because Phoenix sought support from an experienced partner in our industry, and we are happy they chose to work together. The impressive results Phoenix and ValueSetters generated speak for themselves and we look forward to collaborating with both of them on future offerings.”

About ValueSetters:  Led by a team of professional investors, digital marketing experts, and technology specialists, ValueSetters is a publicly-traded boutique advisory firm with unique expertise in helping early stage companies raise capital over the internet. The company also provides technology consulting services as well as strategic advice to help companies grow and evolve to meet the challenges of today's marketplace.  For more information, visit our website at https://valuesetters.com.

About Phoenix PharmaLabs: Phoenix PharmaLabs (PPL) is a preclinical drug discovery company dedicated to the development of potent, non-addictive treatment for pain and treatments for addiction. For more information, please visit our website at https://phoenixpharmalabs.com.

About NetcapitalNetcapital is a private securities platform that makes capital markets work for real people. The portal connects investors to entrepreneurs to help private companies grow. The Netcapital funding portal is registered with the U.S. Securities and Exchange Commission (SEC) and is a member of the Financial Industry Regulatory Authority (FINRA), a registered national securities association, as required by SEC rules.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Coreen Kraysler, CFA
ckraysler@valuesetters.com